Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc.

Nucro-Technics is a pharmaceutical contract research organization that conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. In addition, it provides consulting services, especially in quality control and assurance as well as in Natural Health Product Regulations.

Frontage Holdings Corporation today announced that Dr. Abdul Mutlib has been promoted to CEO of the company, a role in which he succeeds Frontage’s founder Dr. Song Li, who will remain as Executive Chairman of the Board of Directors. Dr. John Lin has been promoted to President of Frontage Laboratories, Inc., the company’s wholly-owned subsidiary. Dr. Mutlib and Dr. Lin will each assume their new roles effective as of today. As Executive Chairman, Dr. Li will continue to actively participate in the company’s leadership and focus on strategic growth opportunities.